Effectiveness and safety of imipenem/clavulanate and linezolid to treat multidrug and extensively drug-resistant tuberculosis at a referral hospital in brazil

Revista Portuguesa de Pneumologia (English Edition)

Volumn 22, Issue 6, 2016, Pages 337-341

  Arbex, M A ^a,b   Bonini, E H ^a,b   Kawakame Pirolla, G ^b   D'Ambrosio L ^c,d   Centis, R ^c   Migliori, G B ^c  

^a University Center of Araraquara   (Brazil)

^b Hospital Nestor Goulart Reis   (Brazil)

^c IRCCS   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

Author keywords

Effectiveness; Imipenem; Linezolid; MDR TB; Safety; Tolerability; XDR TB

Indexed keywords

AMOXICILLIN; CLAVULANIC ACID; EFAVIRENZ; IMIPENEM; LAMIVUDINE; LINEZOLID; TENOFOVIR; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR;

ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; BRAZIL; CLINICAL ARTICLE; DIABETES MELLITUS; DIARRHEA; DRUG ABUSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SAFETY; FEMALE; HEALTH CARE FACILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HUMAN; HYPERTENSION; MALE; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SPUTUM CULTURE; ADOLESCENT; COMBINATION DRUG THERAPY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; MIDDLE AGED; PATIENT REFERRAL; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BRAZIL; CLAVULANIC ACID; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; IMIPENEM; LINEZOLID; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85005981023     PISSN: None     EISSN: 21735115     Source Type: Journal    
DOI: 10.1016/j.rppnen.2016.06.006     Document Type: Article

References (10)

1. Tiberi S, Payen MC, Sotgiu G, D’Ambrosio L, Alarcon Guizado V, Alffenaar JW, et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDRand XDR-TB. Eur Respir J. 2016;47:1235-43.
2. Tiberi S, D’Ambrosio L, De Lorenzo S, Viggiani P, Centis R, Sotgiu G, et al. Ertapenem in the treatment of multidrugresistant tuberculosis: first clinical experience. Eur Respir J. 2016;47:333-6.
3. Tiberi S, Sotgiu G, D’Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, et al. Comparison of effectiveness and safety of imipenem/clavulanateversus meropenem/clavulanatecontaining regimens in the treatment of MDRand XDR-TB. Eur Respir J. 2016, http://dx.doi.org/10.1183/13993003.00214-2016 [Epub ahead of print].
4. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, DeRiemer K, Centis R, et al. Drug resistance beyond extensively drug resistant tuberculosis: individual patient data meta-analysis. Eur Respir J. 2013;42:169-79.
5. Caminero JA, Scardigli A. Classification of antituberculosis drugs: a new proposal based on the most recent evidence. Eur Respir J. 2015;46:887-93.
6. Chambers HF, Turner J, Schecter GF, Kawamura M, Hopewell PC. Imipenem for treatment of tuberculosis in mice and humans. Antimicrob Agents Chemother. 2005;49:2816-3282.
7. Sotgiu G, D’Ambrosio L, Centis R, Tiberi S, Esposito S, Dore S, et al. Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review. Int J Mol Sci. 2016;17.
8. Sotgiu G, Centis R, D’Ambrosio L, Alffenaar J, Anger H, Caminero J, et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J. 2012;40:1430-42.
9. Arbex MA, Ribeiro de Siqueira H, D’Ambrosio L, Migliori GB. The challenge of managing the extensively drug-resistant tuberculosis at a referral hospital in the state of São Paulo, Brazil: a report of three cases. J Bras Pneumol. 2015;41:554-9.
10. Tiberi S, Sotgiu G, D’Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, et al. Effectiveness and safety of imipenemclavulanate added to an optimized background regimen (OBR) versus OBR control regimens in the treatment of multidrugresistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2016;62:1188-90